Skip to main navigation Skip to search Skip to main content

Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: A California cancer consortium phase II trial (NCI 9303)

  • Karen L. Reckamp
  • , Paul H. Frankel
  • , Nora Ruel
  • , Philip C. Mack
  • , Barbara J. Gitlitz
  • , Tianhong Li
  • , Marianna Koczywas
  • , Shirish M. Gadgeel
  • , Mihaela C. Cristea
  • , Chandra P. Belani
  • , Edward M. Newman
  • , David R. Gandara
  • , Primo N. Lara

Research output: Contribution to journal › Article › peer-review

33   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: A California cancer consortium phase II trial (NCI 9303)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science